scholarly journals Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice

2021 ◽  
Author(s):  
Marin Kunimoto ◽  
Yasutomo Imai ◽  
Masako Matsutani ◽  
Minori Nakatani‐Kusakabe ◽  
Makoto Nagai ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Practice ◽  
Disease Control ◽  
Real World ◽  
Control Tool

Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real‐world clinical practice

2021 ◽  
Author(s):  
Masako Matsutani ◽  
Yasutomo Imai ◽  
Yukako Inoue ◽  
Minori Nakatani‐Kusakabe ◽  
Masaru Natsuaki ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Practice ◽  
Real World ◽  
Tacrolimus Ointment

scholarly journals Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

Allergy ◽  
2017 ◽  
Vol 72 (6) ◽  
pp. 994-998 ◽  
Author(s):  
A. Zanichelli ◽  
M. Maurer ◽  
W. Aberer ◽  
T. Caballero ◽  
H. J. Longhurst ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World

scholarly journals How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia

Blood ◽  
2019 ◽  
Vol 133 (12) ◽  
pp. 1298-1307 ◽  
Author(s):  
Deborah M. Stephens ◽  
John C. Byrd
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Real World ◽  
Lymphocytic Leukemia ◽  
Targeted Therapeutics ◽  
Therapeutic Approaches ◽  
Therapeutic Alternatives

Abstract Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients. With its widespread use in clinical practice, ibrutinib’s common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, and arthralgias have been reported. The management of ibrutinib’s adverse events often cannot be generalized but must be individualized to the patient and their long-term risk of additional complications. When ibrutinib was initially developed, there were limited therapeutic alternatives for CLL, which often resulted in treating through the adverse events. At the present time, there are several effective alternative agents available, so transition to an alternative CLL directed therapy may be considered. Given the continued expansion of ibrutinib across many therapeutic areas, investigation of the pathogenesis of adverse events with this agent and also clinical trials examining therapeutic approaches for complications arising during therapy are needed. Herein, we provide strategies we use in real-world CLL clinical practice to address common adverse events associated with ibrutinib.

Patterns of hedgehog inhibitor (HHI) treatment interruptions and re-initiations among patients with basal cell carcinoma (BCC) in real-world clinical practice.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19349-e19349
Author(s):  
Jessica J. Jalbert ◽  
Chieh-I Chen ◽  
Ning Wu ◽  
Matthew G. Fury ◽  
Emily S Ruiz ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Treatment Duration ◽  
Index Date ◽  
Sensitivity Analyses ◽  
Kaplan Meier ◽  
Treatment Interruptions ◽  
Observational Cohort ◽  
Practice Methods

e19349 Background: HHIs are oral targeted therapies approved for the treatment of advanced BCC but treatment-related adverse events may result in treatment interruptions or discontinuation. The objective of this study was to describe HHI treatment patterns among patients with BCC in real-world clinical practice. Methods: We conducted an observational cohort study using MarketScan Commercial/Medicare databases (01/01/2013–09/30/2018). We identified new users of HHIs (index date = date of the first dispensation), ≥18 years of age who were continuously enrolled for ≥6 months prior to the index date (i.e. baseline) with ≥1 baseline BCC diagnosis. Treatment interruptions (TI) were defined as a lack of dispensation following the exhaustion of days’ supply and allotted grace period (GP). Re-initiation (RI) was defined as ≥1 HHI dispensation after TI. The Kaplan–Meier method was used to estimate risk and time to TI and, among patients with a TI, incidence of RI. HHIs are generally dispensed in 30-days’ supply and indicated as long as a patient derives a clinical benefit; however, since TIs are commonly employed during HHI therapy, sensitivity analyses were conducted using GPs of 14, 30, 60, 90, and 120 days. Results: We identified 469 patients with a BCC diagnosis initiating HHIs. The mean (SD) age was 67.6 (15.8) years, 64.2% were men, 51.2% were covered by commercial insurance, and 99.2% initiated vismodegib. Using a GP of 14, 30, 60, 90, and 120 days, the risk of TI was 79.2%, 68.8%, 60.0%, 55.4%, and 51.4% at 6 months and 94.8%, 91.3%, 88.2%, 83.2%, and 80.2% at 1 year, respectively. Median HHI treatment duration ranged from 94 days (95% CI: 90–109) using a GP of 14 days to 173 days (95% CI: 156–194) using a GP of 120 days. At 6 months following TI, incidence of RI was 35.8%, 19.8%, 11.3%, 6.9%, and 4.9% using a GP of 14, 30, 60, 90, and 120 days, respectively. The incidence of HHI RI at 1-year following TI ranged from 40.8% using a 14-day GP to 13.4% using a 120-day GP. Conclusions: Median HHI treatment duration was approximately 6 months, even after allowing for a 120-day GP. Median treatment duration was considerably shorter than what has been reported in clinical trials. Our results suggest that long-term HHI therapy may be difficult in a real-world setting.

Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting Stent in real-world clinical practice

2008 ◽  
Vol 4 (3) ◽  
pp. 338-344 ◽  
Author(s):  
Chi-Hang Lee ◽  
Adrian Low ◽  
Eric Hong ◽  
Bee-Choo Tai ◽  
Ing-Haan Lim ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document